表紙:小児神経芽細胞腫治療の世界市場(2022年~2028年):治療タイプ別、流通チャネル別、地域別の市場規模調査と予測
市場調査レポート
商品コード
1084088

小児神経芽細胞腫治療の世界市場(2022年~2028年):治療タイプ別、流通チャネル別、地域別の市場規模調査と予測

Global Pediatric Neuroblastoma Treatment Market Size study, by Treatment Type (Chemotherapy, Immunotherapy, and Others), by Distribution Channel (Hospital Pharmacies and Retail Pharmacies) and Regional Forecasts 2022-2028

出版日: | 発行: Bizwit Research & Consulting LLP | ページ情報: 英文 | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.41円
小児神経芽細胞腫治療の世界市場(2022年~2028年):治療タイプ別、流通チャネル別、地域別の市場規模調査と予測
出版日: 2022年05月27日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の小児神経芽細胞腫治療の市場規模は、2022年~2028年の予測期間中に6%を超える健全な成長率で拡大すると予想されています。市場を牽引する主な要因には、小児神経芽細胞腫の有病率の上昇や、研究開発の増加、利用可能ながん治療法の認知度の向上などがあります。さらに、小児部門の医療インフラを整備するための研究開発プログラムへの政府投資の増加、小児神経芽細胞腫治療に対する認知度の向上、小児神経芽細胞腫における化学療法の有効性を評価するための投資の増加も、市場を促進します。しかし、小児神経芽細胞腫の治療費が高いことが、市場拡大の大きな障害となっています。

当レポートでは世界の小児神経芽細胞腫治療市場を調査し、市場の概要、市場の促進要因・抑制要因の分析、市場機会、COVID-19の影響、セグメント別の市場分析、競合情勢、主要企業のプロファイルなど、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 世界の小児神経芽細胞腫治療市場:定義と範囲

第3章 世界の小児神経芽細胞腫治療:市場力学

  • 小児神経芽細胞腫治療市場:影響分析(2020年~2028年)

第4章 世界の小児神経芽細胞腫治療市場:業界分析

  • ポーターのファイブフォースモデル
  • PEST分析
  • 投資採用モデル
  • アナリストの推奨事項と結論
  • 主要な投資機会
  • 主要な成功戦略

第5章 リスク評価:COVID-19の影響

    • 業界に対するCOVID-19の全体的な影響の評価
    • COVID-19以前およびCOVID-19後の市場シナリオ

第6章 世界の小児神経芽細胞腫治療市場:治療タイプ別

  • 市場のスナップショット
  • 実績:潜在的な分析
  • 市場規模の推計と予測(2018年~2028年)
  • サブセグメント分析
    • 化学療法
    • 免疫療法
    • その他

第7章 世界の小児神経芽細胞腫治療市場:流通チャネル別

  • 市場のスナップショット
  • 実績:潜在的な分析
  • 市場規模の推計と予測(2018年~2028年)
  • サブセグメント分析
    • 病院薬局
    • 小売薬局

第8章 世界の小児神経芽細胞腫治療市場:地域分析

  • 地域市場のスナップショット
  • 北米
    • 米国
    • カナダ
  • 欧州のスナップショット
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • アジア太平洋地域のスナップショット
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
    • その他アジア太平洋地域
  • ラテンアメリカのスナップショット
    • ブラジル
    • メキシコ
  • その他の地域

第9章 競合情勢

  • 主な市場戦略
  • 企業プロファイル
    • United Therapeutics Corporation
    • APEIRON Biologics AG
    • Baxter International
    • Pfizer, Inc.
    • Bayer AG
    • MacroGenics, Inc.
    • Sartorius AG
    • CELLECTAR BIOSCIENCES, INC.
    • PROVECTUS BIOPHARMACEUTICALS, INC.
    • Y-mAbs Therapeutics, Inc.

第10章 調査プロセス

図表

LIST OF TABLES

  • TABLE 1. Global Pediatric Neuroblastoma Treatment Market, report scope
  • TABLE 2. Global Pediatric Neuroblastoma Treatment Market estimates & forecasts by Region 2018-2028 (USD Billion)
  • TABLE 3. Global Pediatric Neuroblastoma Treatment Market estimates & forecasts by Treatment Type 2018-2028 (USD Billion)
  • TABLE 4. Global Pediatric Neuroblastoma Treatment Market estimates & forecasts by Distribution Channel 2018-2028 (USD Billion)
  • TABLE 5. Global Pediatric Neuroblastoma Treatment Market by segment, estimates & forecasts, 2018-2028 (USD Billion)
  • TABLE 6. Global Pediatric Neuroblastoma Treatment Market by region, estimates & forecasts, 2018-2028 (USD Billion)
  • TABLE 7. Global Pediatric Neuroblastoma Treatment Market by segment, estimates & forecasts, 2018-2028 (USD Billion)
  • TABLE 8. Global Pediatric Neuroblastoma Treatment Market by region, estimates & forecasts, 2018-2028 (USD Billion)
  • TABLE 9. Global Pediatric Neuroblastoma Treatment Market by segment, estimates & forecasts, 2018-2028 (USD Billion)
  • TABLE 10. Global Pediatric Neuroblastoma Treatment Market by region, estimates & forecasts, 2018-2028 (USD Billion)
  • TABLE 11. Global Pediatric Neuroblastoma Treatment Market by segment, estimates & forecasts, 2018-2028 (USD Billion)
  • TABLE 12. Global Pediatric Neuroblastoma Treatment Market by region, estimates & forecasts, 2018-2028 (USD Billion)
  • TABLE 13. Global Pediatric Neuroblastoma Treatment Market by segment, estimates & forecasts, 2018-2028 (USD Billion)
  • TABLE 14. Global Pediatric Neuroblastoma Treatment Market by region, estimates & forecasts, 2018-2028 (USD Billion)
  • TABLE 15. U.S. Pediatric Neuroblastoma Treatment Market estimates & forecasts, 2018-2028 (USD Billion)
  • TABLE 16. U.S. Pediatric Neuroblastoma Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 17. U.S. Pediatric Neuroblastoma Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 18. Canada Pediatric Neuroblastoma Treatment Market estimates & forecasts, 2018-2028 (USD Billion)
  • TABLE 19. Canada Pediatric Neuroblastoma Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 20. Canada Pediatric Neuroblastoma Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 21. UK Pediatric Neuroblastoma Treatment Market estimates & forecasts, 2018-2028 (USD Billion)
  • TABLE 22. UK Pediatric Neuroblastoma Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 23. UK Pediatric Neuroblastoma Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 24. Germany Pediatric Neuroblastoma Treatment Market estimates & forecasts, 2018-2028 (USD Billion)
  • TABLE 25. Germany Pediatric Neuroblastoma Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 26. Germany Pediatric Neuroblastoma Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 27. RoE Pediatric Neuroblastoma Treatment Market estimates & forecasts, 2018-2028 (USD Billion)
  • TABLE 28. RoE Pediatric Neuroblastoma Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 29. RoE Pediatric Neuroblastoma Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 30. China Pediatric Neuroblastoma Treatment Market estimates & forecasts, 2018-2028 (USD Billion)
  • TABLE 31. China Pediatric Neuroblastoma Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 32. China Pediatric Neuroblastoma Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 33. India Pediatric Neuroblastoma Treatment Market estimates & forecasts, 2018-2028 (USD Billion)
  • TABLE 34. India Pediatric Neuroblastoma Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 35. India Pediatric Neuroblastoma Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 36. Japan Pediatric Neuroblastoma Treatment Market estimates & forecasts, 2018-2028 (USD Billion)
  • TABLE 37. Japan Pediatric Neuroblastoma Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 38. Japan Pediatric Neuroblastoma Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 39. RoAPAC Pediatric Neuroblastoma Treatment Market estimates & forecasts, 2018-2028 (USD Billion)
  • TABLE 40. RoAPAC Pediatric Neuroblastoma Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 41. RoAPAC Pediatric Neuroblastoma Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 42. Brazil Pediatric Neuroblastoma Treatment Market estimates & forecasts, 2018-2028 (USD Billion)
  • TABLE 43. Brazil Pediatric Neuroblastoma Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 44. Brazil Pediatric Neuroblastoma Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 45. Mexico Pediatric Neuroblastoma Treatment Market estimates & forecasts, 2018-2028 (USD Billion)
  • TABLE 46. Mexico Pediatric Neuroblastoma Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 47. Mexico Pediatric Neuroblastoma Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 48. RoLA Pediatric Neuroblastoma Treatment Market estimates & forecasts, 2018-2028 (USD Billion)
  • TABLE 49. RoLA Pediatric Neuroblastoma Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 50. RoLA Pediatric Neuroblastoma Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 51. Row Pediatric Neuroblastoma Treatment Market estimates & forecasts, 2018-2028 (USD Billion)
  • TABLE 52. Row Pediatric Neuroblastoma Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 53. Row Pediatric Neuroblastoma Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 54. List of secondary sources, used in the study of global Pediatric Neuroblastoma Treatment Market
  • TABLE 55. List of primary sources, used in the study of global Pediatric Neuroblastoma Treatment Market
  • TABLE 56. Years considered for the study
  • TABLE 57. Exchange rates considered

LIST OF FIGURES

List of figures

  • FIG 1. Global Pediatric Neuroblastoma Treatment Market, research methodology
  • FIG 2. Global Pediatric Neuroblastoma Treatment Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Pediatric Neuroblastoma Treatment Market, key trends 2021
  • FIG 5. Global Pediatric Neuroblastoma Treatment Market, growth prospects 2022-2028
  • FIG 6. Global Pediatric Neuroblastoma Treatment Market, porters 5 force model
  • FIG 7. Global Pediatric Neuroblastoma Treatment Market, pest analysis
  • FIG 8. Global Pediatric Neuroblastoma Treatment Market, value chain analysis
  • FIG 9. Global Pediatric Neuroblastoma Treatment Market by segment, 2018 & 2028 (USD Billion)
  • FIG 10. Global Pediatric Neuroblastoma Treatment Market by segment, 2018 & 2028 (USD Billion)
  • FIG 11. Global Pediatric Neuroblastoma Treatment Market by segment, 2018 & 2028 (USD Billion)
  • FIG 12. Global Pediatric Neuroblastoma Treatment Market by segment, 2018 & 2028 (USD Billion)
  • FIG 13. Global Pediatric Neuroblastoma Treatment Market by segment, 2018 & 2028 (USD Billion)
  • FIG 14. Global Pediatric Neuroblastoma Treatment Market, regional snapshot 2018 & 2028
  • FIG 15. North America Pediatric Neuroblastoma Treatment Market 2018 & 2028 (USD Billion)
  • FIG 16. Europe Pediatric Neuroblastoma Treatment Market 2018 & 2028 (USD Billion)
  • FIG 17. Asia Pacific Pediatric Neuroblastoma Treatment Market 2018 & 2028 (USD Billion)
  • FIG 18. Latin America Pediatric Neuroblastoma Treatment Market 2018 & 2028 (USD Billion)
  • FIG 19. Global Pediatric Neuroblastoma Treatment Market, company Market share analysis (2021)
目次

Global Pediatric Neuroblastoma Treatment Market is valued at approximately XX in 2021 and is anticipated to grow with a healthy growth rate of more than 6% over the forecast period 2022-2028. The most common type of extracranial solid tumour in children is neuroblastoma. The rising prevalence of neuroblastoma in children, as well as increased research and development and increased awareness of available cancer treatments, are all contributing to the market's growth. Neuroblastoma is estimated to affect one out of every 7,000 live births, according to a National Cancer Institute article published in February 2022. In children under the age of 15, the annual incidence is 10.54 cases per 1 million. Around 37% of patients are diagnosed as infants, and 90% are under the age of 5, with a median age of 19 months at diagnosis. Furthermore, the government's increasing investments in research and development programmes to develop the medical infrastructure in the paediatric section, as well as increased awareness of paediatric neuroblastoma treatment, are boosting the market growth. Furthermore, increasing investments in evaluating the efficacy of chemotherapy in paediatric neuroblastoma will propel the market forward. For example, in January 2022, Jason Shohet, MD, PhD, was awarded a new two-year USD 300,000 Scholar Hope Grant to focus on drug resistance in neuroblastoma chemotherapy treatments. It is a cancer of the peripheral nervous system that is fatal in children. However, the high cost of paediatric neuroblastoma treatment is a significant impediment to market expansion.

The key regions considered for the global Pediatric Neuroblastoma Treatment market study include: Asia Pacific, North America, Europe, Latin America, and Rest of the World. Throughout the forecast period, North America is expected to dominate the overall market. The high prevalence of paediatric neuroblastoma in the region, as well as established healthcare infrastructure, are some of the key factors responsible for the region's large market share. Additionally, favourable government initiatives and an increase in the number of research partnerships are expected to drive market growth. The Asia Pacific (APAC) region, on the other hand, will grow at a steady pace over the forecast period. Increased public investment and improvements in healthcare infrastructure will be attributed to this growth.

Major market players included in this report are:

  • United Therapeutics Corporation
  • APEIRON Biologics AG
  • Baxter International
  • Pfizer, Inc.
  • Bayer AG
  • MacroGenics, Inc.
  • Sartorius AG
  • CELLECTAR BIOSCIENCES, INC.
  • PROVECTUS BIOPHARMACEUTICALS, INC.
  • Y-mAbs Therapeutics, Inc.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Treatment Type:

  • Chemotherapy
  • Immunotherapy
  • Others

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies

By Region:

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Italy
    • ROE
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • RoAPAC
  • Latin America
    • Brazil
    • Mexico
  • Rest of the World

Furthermore, years considered for the study are as follows:

  • Historical year - 2018, 2019, 2020
  • Base year - 2021
  • Forecast period - 2022 to 2028

Target Audience of the Global Pediatric Neuroblastoma Treatment Market in Market Study:

  • Key Consulting Companies & Advisors
  • Large, medium-sized, and small enterprises
  • Venture capitalists
  • Value-Added Resellers (VARs)
  • Third-party knowledge providers
  • Investment bankers
  • Investors

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2028 (USD Billion)
    • 1.2.1. Pediatric Neuroblastoma Treatment Market, by Region, 2020-2028 (USD Billion)
    • 1.2.2. Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2020-2028 (USD Billion)
    • 1.2.3. Pediatric Neuroblastoma Treatment Market, by Distribution Channel, 2020-2028 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Pediatric Neuroblastoma Treatment Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Pediatric Neuroblastoma Treatment Market Dynamics

  • 3.1. Pediatric Neuroblastoma Treatment Market Impact Analysis (2020-2028)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing burden of pediatric neuroblastoma coupled with increasing R&D
      • 3.1.1.2. Rise in awareness of available treatment for cancer
    • 3.1.2. Market Challenges
      • 3.1.2.1. High cost and side effects associated with cancer therapy
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Intensive research and development

Chapter 4. Global Pediatric Neuroblastoma Treatment Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
    • 4.1.6. Futuristic Approach to Porter's 5 Force Model (2018-2028)
  • 4.2. PEST Analysis
    • 4.2.1. Political
    • 4.2.2. Economical
    • 4.2.3. Social
    • 4.2.4. Technological
  • 4.3. Investment Adoption Model
  • 4.4. Analyst Recommendation & Conclusion
  • 4.5. Top investment opportunity
  • 4.6. Top winning strategies

Chapter 5. Risk Assessment: COVID-19 Impact

    • 5.1.1. Assessment of the overall impact of COVID-19 on the industry
    • 5.1.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Pediatric Neuroblastoma Treatment Market, by Treatment Type

  • 6.1. Market Snapshot
  • 6.2. Global Pediatric Neuroblastoma Treatment Market by Treatment Type, Performance - Potential Analysis
  • 6.3. Global Pediatric Neuroblastoma Treatment Market Estimates & Forecasts by Treatment Type, 2018-2028 (USD Billion)
  • 6.4. Pediatric Neuroblastoma Treatment Market, Sub Segment Analysis
    • 6.4.1. Chemotherapy
    • 6.4.2. Immunotherapy
    • 6.4.3. Others

Chapter 7. Global Pediatric Neuroblastoma Treatment Market, by Distribution Channel

  • 7.1. Market Snapshot
  • 7.2. Global Pediatric Neuroblastoma Treatment Market by Distribution Channel, Performance - Potential Analysis
  • 7.3. Global Pediatric Neuroblastoma Treatment Market Estimates & Forecasts by Distribution Channel, 2018-2028 (USD Billion)
  • 7.4. Pediatric Neuroblastoma Treatment Market, Sub Segment Analysis
    • 7.4.1. Hospital Pharmacies
    • 7.4.2. Retail Pharmacies

Chapter 8. Global Pediatric Neuroblastoma Treatment Market, Regional Analysis

  • 8.1. Pediatric Neuroblastoma Treatment Market, Regional Market Snapshot
  • 8.2. North America Pediatric Neuroblastoma Treatment Market
    • 8.2.1. U.S. Pediatric Neuroblastoma Treatment Market
      • 8.2.1.1. Treatment Type breakdown estimates & forecasts, 2018-2028
      • 8.2.1.2. Distribution Channel breakdown estimates & forecasts, 2018-2028
    • 8.2.2. Canada Pediatric Neuroblastoma Treatment Market
  • 8.3. Europe Pediatric Neuroblastoma Treatment Market Snapshot
    • 8.3.1. U.K. Pediatric Neuroblastoma Treatment Market
    • 8.3.2. Germany Pediatric Neuroblastoma Treatment Market
    • 8.3.3. France Pediatric Neuroblastoma Treatment Market
    • 8.3.4. Spain Pediatric Neuroblastoma Treatment Market
    • 8.3.5. Italy Pediatric Neuroblastoma Treatment Market
    • 8.3.6. Rest of Europe Pediatric Neuroblastoma Treatment Market
  • 8.4. Asia-Pacific Pediatric Neuroblastoma Treatment Market Snapshot
    • 8.4.1. China Pediatric Neuroblastoma Treatment Market
    • 8.4.2. India Pediatric Neuroblastoma Treatment Market
    • 8.4.3. Japan Pediatric Neuroblastoma Treatment Market
    • 8.4.4. Australia Pediatric Neuroblastoma Treatment Market
    • 8.4.5. South Korea Pediatric Neuroblastoma Treatment Market
    • 8.4.6. Rest of Asia Pacific Pediatric Neuroblastoma Treatment Market
  • 8.5. Latin America Pediatric Neuroblastoma Treatment Market Snapshot
    • 8.5.1. Brazil Pediatric Neuroblastoma Treatment Market
    • 8.5.2. Mexico Pediatric Neuroblastoma Treatment Market
  • 8.6. Rest of The World Pediatric Neuroblastoma Treatment Market

Chapter 9. Competitive Intelligence

  • 9.1. Top Market Strategies
  • 9.2. Company Profiles
    • 9.2.1. United Therapeutics Corporation
      • 9.2.1.1. Key Information
      • 9.2.1.2. Overview
      • 9.2.1.3. Financial (Subject to Data Availability)
      • 9.2.1.4. Product Summary
      • 9.2.1.5. Recent Developments
    • 9.2.2. APEIRON Biologics AG
    • 9.2.3. Baxter International
    • 9.2.4. Pfizer, Inc.
    • 9.2.5. Bayer AG
    • 9.2.6. MacroGenics, Inc.
    • 9.2.7. Sartorius AG
    • 9.2.8. CELLECTAR BIOSCIENCES, INC.
    • 9.2.9. PROVECTUS BIOPHARMACEUTICALS, INC.
    • 9.2.10. Y-mAbs Therapeutics, Inc.

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
  • 10.3. Research Assumption